Solubility and dissolution enhancement of saquinavir mesylate by inclusion complexation technique

  • Hitendra S. Mahajan
  • Mayur H. Pingale
  • Kapil M. Agrawal
Short Communication


The objective of the present study was to formulate inclusion complex of saquinavir mesylate to improve the aqueous solubility and dissolution rate. Saquinavir mesylate is a BCS class II drug having low aqueous solubility and therefore low oral bioavailability. In the present study, inclusion complex of saquinavir mesylate with hydroxypropyl-β-cyclodextrin were prepared by kneading method. Inclusion complex were characterized by differential scanning calorimetry (DSC), X-ray diffractometry (XRD), 1H NMR studies, and Fourier transform infrared spectroscopy and evaluated for in vitro dissolution, and phase solubility studies. DSC and XRD study demonstrated that there was a significant decrease in crystallinity of pure drug present in inclusion complex, which resulted in an increased dissolution rate of saquinavir mesylate and 1H NMR studies strongly, confirmed that the inclusion complex has formed. Inclusion complexation results in improvement in solubility and dissolution rate. The inclusion complexation would be suitable method for dissolution and bioavailability enhancement of saquinavir mesylate.


HPβCD Inclusion complexation Saquinavir mesylate Kneading method Dissolution enhancement 



Authors are thankful to Panacea Biotech Pvt. Ltd., Mumbai, India, for providing gift sample of saquinavir mesylate. The authors are also grateful to Principal (R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur) for providing necessary facilities and infrastructure for carrying out this work. Support of Mr. Vipul Rane, is kindly acknowledged.


  1. 1.
    Hite, M., Turner, S.: Oral delivery of poorly soluble drugs pharmaceutical manufacturing and packing sourcer. Summer 3, 400 (2003)Google Scholar
  2. 2.
    Amidon, G., Lennernas, H., Shah, V., Crison, J.: A theoretical basis for a biopharmaceutical drug classification: the correlation of in vivo drug product dissolution and in vivo bioavailability. Pharm. Res. 12, 413–420 (1995)CrossRefGoogle Scholar
  3. 3.
    Basanta Kumar Reddy, B., Karunakar, A.: Biopharmaceutics classification system: a regulatory approach. Dissol. Technol. 18, 31–37 (2011)Google Scholar
  4. 4.
    Antoniadou-Vyza, E., Buckton, G., Michaleas, S.G., Loukas, Y.L., Efentakis, M.: The formation of inclusion complex of methocarbamol with hydroxypropyl-β-cyclodextrin: the effect of chemical stability, solubility and dissolution rate. Int. J. Pharm. 158(2), 233–239 (1997)CrossRefGoogle Scholar
  5. 5.
    Mahajan, H.S., Shah, S.K., Surana, S.J.: Nasal in situ gel containing hydroxypropyl-β-cyclodextrin of artemether: development and in vitro evaluation. J. Incl. Phenom. Macrocycl. Chem. 70, 49–58 (2011)CrossRefGoogle Scholar
  6. 6.
    Yang, B., Lin, J., Chen, Y., Lin, Y.: Artemether/hydroxypropyl-β-cyclodextrin host–guest system: characterization, phase solubility and inclusion mode. J. Bioorg. Med. Chem. 17, 6311–6317 (2009)CrossRefGoogle Scholar
  7. 7.
    Rawat, S., Jain, S.K.: Solubility enhancement of celecoxib using β-cyclodextrin inclusion complexes. Eur. J. Pharm. Biopharm. 54, 63–267 (2004)Google Scholar
  8. 8.
    Nandi, S., Debnath, S., Manjunath, S.Y., Mallareddy, V., Babre, N.P., Gopal Rao, M.: Improvement of dissolution characteristics of meloxicam by complexation with cyclodextrins. Int. J. Pharm. Sci. Nano. 3(4), 1263–1270 (2011)Google Scholar
  9. 9.
    Boudad, H., Legrand, P., Lebas, G., Cheron, M., Duchene, D., Ponchel, G.: Combined hydroxypropyl-beta-cyclodextrin and poly (alkylcyanoacrylate) nanoparticles intended for oral administration of saquinavir. Int. J. Pharm. 218, 113–124 (2001)CrossRefGoogle Scholar
  10. 10.
    Pinnamaneni, S., Das, N., Das, S.: Formulation approaches for orally administered poorly soluble drugs. Pharmazie 57, 291–300 (2002)Google Scholar
  11. 11.
    Nalluri, B.N., Chowdary, K.P.R., Murthy, K.V.R., Hayman, A.R., Becket, G.: Physicochemical characterization and dissolution properties of nimesulide cyclodextrin binary systems. PharmSciTech 4(1), 1–12 (2003)CrossRefGoogle Scholar
  12. 12.
    Amit, K., Rajesh, V., Suresh, P., Anil, B.: Innovation of cyclodextrin in novel drug delivery system. J. Nat. Consci. 2(1), 293–305 (2011)Google Scholar
  13. 13.
    Buchanan, C.M., Buchanan, N.L., Edgar, K.J., Little, J.L., Ramsey, M.G., Ruble, K.M., Wacher, V.J., Wempe, M.F.: Pharmacokinetics of saquinavir after intravenous and oral dosing of saquinavir: hydroxybutenyl-β-cyclodextrin formulations. Biomacromolecules 9(1), 305–313 (2008)CrossRefGoogle Scholar
  14. 14.
    Higuchi, T., Connors, K.A.: Phase-solubility techniques. Adv. Anal. Chem. Instrum. 4, 117–122 (1965)Google Scholar
  15. 15.
    Silverstein, R.M., Webster, F.X., Kiemle, D.J.: Spectrophotometric identification of organic compounds, pp. 150–151. Wiley, Hoboken (2005)Google Scholar
  16. 16.
    Pathak, S.M., Musmade, P., Dengle, S., Karthik, A., Bhat, K., Udupa, N.: Enhanced oral absorption of saquinavir with methyl-beta-cyclodextrin—preparation and in vitro and in vivo evaluation. Eur. J. Pharm. Sci. 41, 440–451 (2010)CrossRefGoogle Scholar
  17. 17.
    Subramaniam, P., Mohamad, S., Alias, Y.: Synthesis and characterization of the inclusion complex of dicationic ionic liquid and β-cyclodextrin. Int. J. Mol. Sci. 12(9), 6329–6345 (2011)Google Scholar
  18. 18.
    Nicolescu, C., Aramă, C., Monciu, C.-M.: Preparation and characterization of inclusion complexes between repaglinide and β-cyclodextrin, 2-hydroxypropyl-β-cyclodextrin and randomly methylated-β-cyclodextrin. Farmacia 58, 78–88 (2010)Google Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  • Hitendra S. Mahajan
    • 1
  • Mayur H. Pingale
    • 1
  • Kapil M. Agrawal
    • 1
  1. 1.R. C. Patel Institute of Pharmaceutical Education and ResearchShirpurIndia

Personalised recommendations